Navigation Links
United Therapeutics Corporation Reports Second Quarter 2011 Financial Results
Date:7/28/2011

SILVER SPRING, Md., July 28, 2011 /PRNewswire/ -- United Therapeutics Corporation (NASDAQ: UTHR) today announced its financial results for the quarter ended June 30, 2011.

"I'm pleased with the successful unblinding of the FREEDOM-M study this quarter, as well as the very good operating results we achieved," remarked Martine Rothblatt, Ph.D., United Therapeutics' Chairman and Chief Executive Officer. "We remain on track to reach our 2011 forecast for revenues of $750 million, with a plus/minus margin of 5 percent."Total revenues for the quarter ended June 30, 2011 were $183.8 million, up from $134.7 million for the quarter ended June 30, 2010. Net income for the quarter ended June 30, 2011, was $73.9 million, or $1.27 per basic share, compared to $37.7 million, or $0.67 per basic share, for the same quarter in 2010. Gross margin from sales was $162.4 million for the quarter ended June 30, 2011, compared to $119.2 million for the same quarter last year. Earnings before non-cash charges(1) for the quarter ended June 30, 2011 were $93.5 million, compared to $65.7 million for the quarter ended June 30, 2010.

Results for the three- and six-month periods ended June 30, 2011 and June 30, 2010 do not include the results of Medicomp, Inc., our former telemedicine subsidiary, which we sold during the first quarter of 2011. The results of Medicomp, Inc. have been reported within discontinued operations on our consolidated statements of operations below.

(1) See definition of earnings before non-cash charges, a non-GAAP financial measure, and a reconciliation of net income to earnings before non-cash charges below.

Financial Results for the Three Months Ended June 30, 2011Revenues

The table below summarizes the components of net revenues (dollars in thousands):Three Months EndedJune 30,20112010Percentage ChangeCardiopulmonary products:Remodulin

$

104,894$

96,3678.8%Tyvaso

61,80929,483109.6%Adcirca

16,8438,58996.1%Other

205282(27.3)%Total net revenues

$

183,751$

134,72136.4%Revenues for the quarter ended June 30, 2011 increased by $49.0 million, compared to the quarter ended June 30, 2010. The growth in revenues primarily reflects the increase in the number of patients being prescribed our products.

Expenses

The table below summarizes research and development expense by major project and non-project components (dollars in thousands):Three Months EndedJune 30,20112010Percentage ChangeProject and non-project component:Cardiopulmonary

$

24,490$

18,61931.5%Share-based compensation

(9,555)1,420(772.9)%Other

9,3058,5488.9%Total research and development expense

$

24,240$

28,587(15.2)%Cardiopulmonary. The increase in expenses related to our cardiopulmonary projects for the quarter ended June 30, 2011 was attributable largely to increases in expenses related to our FREEDOM-C2 and FREEDOM-M clinical trials and our development of beraprost-MR.

Share-based compensation. The decrease in share-based compensation for the quarter ended June 30, 2011, compared to the same quarter in 2010, corresponded to a reduction in share-based compensation recognized in connection with our share tracking awards plans as a result of the decrease in our stock price.

The table below summarizes selling, general and administrative expense by major categories (in thousands):Three Months EndedJune 30,20112010Percentage ChangeCategory:General and administrative

$

24,268$

18,75429.4%Sales and marketing

17,07212,90032.3%Share-based compensation

(17,484)(2,000)(774.2)%Total selling, general and administrative expense

$

23,856$

29,654(19.6)%General and administrative. The increase in general and administrative expenses for the quarter ended June 30, 2011, compared to the same quarter in 2010, corresponded principally to increases in professional fees in connection with various completed and prospective transactions, and travel expenses, as a result of our growth and increase in business development activities.

Sales and marketing. The increase in sales and marketing expenses for the quarter ended June 30, 2011, compared to the quarter ended June 30, 2010, was attributable to an increase in salaries, as we recently expanded our sales force, and an increase in professional fees in connection with our marketing and advertising initiatives.

Share-based compensation. The decrease in share-based compensation for the quarter ended June 30, 2011, compared to the same quarter in 2010, reflects a reduction in share-based compensation recognized in connection with our share tracking awards plans as a result of the decrease in our stock price.

2011 Revenue GuidanceWe reaffirm our full-year revenue guidance for our three commercial products (Remodulin, Tyvaso and Adcirca), and we continue to expect related revenues to fall within a range of 5% above or below $750 million for 2011.

Earnings Before Non-Cash ChargesEarnings before non-cash charges is defined as net income, adjusted for the following non-cash charges, as applicable: (1) interest; (2) income taxes; (3) license fees; (4) depreciation and amortization; (5) impairment charges; and (6) share-based compensation (stock option and share tracking award expense).

A reconciliation of net income to earnings before non-cash charges is presented below (in thousands, except per share data):Three Months EndedJune 30,20112010Net income, as reported

$

73,891$

37,707Adjust for non-cash charges:Interest expense

5,4314,759Income tax expense

35,72319,212License fees

——Depreciation and amortization

4,8374,582Impairment charges

609—Share-based compensation

(27,037)(574)Earnings before non-cash charges

$

93,454$

65,686Earnings before non-cash charges per share:Basic

$

1.61$

1.17Diluted

$

1.49$

1.09Weighted average number of common shares outstanding:Basic

58,18056,047Diluted

62,75660,393Conference CallWe will host a half-hour teleconference on Thursday, July 28, 2011, at 9:00 a.m. Eastern Time. The teleconference is accessible by dialing 1-877-351-5881, with international callers dialing 1-970-315-0533. A rebroadcast of the teleconference will be available for one week by dialing 1-800-642-1687, with international callers dialing 1-706-645-9291 and using access code 80689472.

This teleconference is also being webcast and can be accessed via our website at http://ir.unither.com/events.cfm.

About United TherapeuticsUnited Therapeutics Corporation is a biotechnology company focused on the development and commercialization of unique products to address the unmet medical needs of patients with chronic and life-threatening conditions.

Non-GAAP Financial InformationThis press release contains a financial measure, earnings before non-cash charges, that does not comply with United States generally accepted accounting principles (GAAP). This measure supplements our financial results prepared in accordance with GAAP as reported below.

We use earnings before non-cash charges to assist us in: (1) planning, including the preparation of our annual operating budget; (2) allocating resources to enhance the financial performance of our business; (3) evaluating the effectiveness of our operational strategies; and (4) evaluating our capacity to fund capital expenditures and expand our business. We believe this non-GAAP financial measure enhances investors' understanding of our financial results by excluding certain expenses that we do not consider when evaluating and comparing the performance of our core operations and making operating decisions. In addition, we have historically reported earnings before non-cash charges to investors, and believe the inclusion of this non-GAAP financial measure provides investors with a consistent method of comparison to historical periods. However, there are limitations in the use of this non-GAAP financial measure in that it excludes certain operating expenses that are recurring in nature. In addition, our calculation of this non-GAAP financial measure may differ from the methodology used by other companies. The presentation of this non-GAAP financial measure should not be considered in isolation or as a substitute for our financial results prepared in accordance with GAAP. A reconciliation of net income, the most directly comparable GAAP financial measure, to earnings before non-cash charges can be found in the table above under the heading, Earnings Before Non-Cash Charges.

Forward-looking StatementsStatements included in this press release that are not historical in nature are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, among others, our expectations about future operating results and the demand for our products, including our guidance for annual revenues. These forward-looking statements are subject to certain risks and uncertainties, such as those described in our periodic reports filed with the Securities and Exchange Commission, that could cause actual results to differ materially from anticipated results. Consequently, such forward-looking statements are qualified by the cautionary statements, cautionary language and risk factors set forth in our periodic reports and documents filed with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K.  We claim the protection of the safe harbor contained in the Private Securities Litigation Reform Act of 1995 for forward-looking statements. We are providing this information as of July 28, 2011, and assume no obligation to update or revise the information contained in this press release whether as a result of new information, future events or any other reason. [uthr-g]

Remodulin and Tyvaso are registered trademarks of United Therapeutics Corporation.

Adcirca is a registered trademark of Eli Lilly and Company.

UNITED THERAPEUTICS CORPORATIONCONSOLIDATED STATEMENTS OF OPERATIONS(In thousands, except per share data)Three Months EndedJune 30,Six Months EndedJune 30,2011201020112010(Unaudited)(Unaudited)Revenues:Net product sales

$

183,546$

134,439$

345,764$

260,071License fees

205282499564Total revenues

183,751134,721346,263260,635Operating expenses:Research and development

24,24028,58771,94763,055Selling, general and administrative

23,85629,65482,11875,106Cost of product sales

21,16215,26140,90028,984Total operating expenses

69,25873,502194,965167,145Operating income

114,49361,219151,29893,490Other (expense) income:Interest income

8398021,5041,746Interest expense

(5,431)(4,759)(10,841)(9,446)Equity loss in affiliate

(30)(44)(67)(91)Other, net

(257)93(1,023)318Total other (expense) income, net

(4,879)(3,908)(10,427)(7,473)Income from continuing operations before income taxes

109,61457,311140,87186,017Income tax expense

(35,723)(19,345)(47,622)(29,106)Income from continuing operations

73,89137,96693,24956,911Discontinued operations:(Loss) income from discontinued operations, net of tax

—(259)76(275)Loss on disposal of discontinued operations, net of tax

——(3,044)—Loss from discontinued operations

—(259)(2,968)(275)Net income

$

73,891$

37,707$

90,281$

56,636Net income per common share:BasicContinuing operations

$

1.27$

0.68$

1.61$

1.03Discontinued operations

$

0.00$

(0.01)$

(0.05)$

(0.01)Net income per basic common share

$

1.27$

0.67$

1.56$

1.02DilutedContinuing operations

$

1.18$

0.63$

1.49$

0.96Discontinued operations

$

0.00$

(0.01)$

(0.05)$

(0.01)Net income per diluted common share

$

1.18$

0.62$

1.44$

0.95Weighted average number of common shares outstanding:Basic

58,18056,04757,96855,411Diluted

62,75660,39362,52559,548SELECTED CONSOLIDATED BALANCE SHEET DATAJune 30, 2011(Unaudited, In thousands)Cash, cash equivalents and marketable securities (excluding restricted amounts of $5.1 million)

$

887,417Total assets

1,578,740Total liabilities and common stock subject to repurchase

576,397Total stockholders' equity

1,002,343
'/>"/>

SOURCE United Therapeutics Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. FDA Advisory Panel Unanimously Recommends Approval of EXCOR(R) Pediatric Ventricular Assist Device for Use in the United States
2. Daiichi Sankyo Selects Veeva CRM to Support Customer Engagement Initiatives in the United Kingdom
3. United Therapeutics Corporation To Announce Second Quarter 2011 Financial Results Before Market Open on Thursday, July 28, 2011
4. United Therapeutics Corporation Completes Enrollment of FREEDOM-C(2) Trial
5. United Therapeutics Corporation Reports 2010 Fourth Quarter and Annual Financial Results
6. United Therapeutics Corporation to Announce Fourth Quarter and Annual 2010 Financial Results Before Market Open on Tuesday, February 15, 2011
7. United Therapeutics Corporation Reports Third Quarter 2010 Financial Results
8. United Therapeutics Corporation to Announce Third Quarter 2010 Financial Results Before Market Open on Thursday, October 28, 2010
9. Sangart, Inc. Receives $1.1 Million Grant Award from the United States Department of Defense for Further Development of MP4 Molecule in Trauma
10. United Therapeutics Corporation to Announce Second Quarter 2010 Financial Results Before Market Open on Wednesday, July 28, 2010
11. Report Details How States Respond to Citizens United Decision
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... ... 2016 , ... Mosio, a leader in clinical research patient ... and Retention Tips.” Partnering with experienced clinical research professionals, Mosio revisits the hurdle ... and strategies for clinical researchers. , “The landscape of how patients receive and ...
(Date:6/23/2016)... - FACIT has announced the creation of a ... Propellon Therapeutics Inc. ("Propellon" or "the Company"), to ... of first-in-class WDR5 inhibitors for the treatment of ... an exciting class of therapies, possessing the potential ... patients. Substantial advances have been achieved with the ...
(Date:6/23/2016)... ... June 23, 2016 , ... Charm Sciences, Inc. is ... has received AOAC Research Institute approval 061601. , “This is another AOAC-RI approval ... Bob Salter, Vice President of Regulatory and Industrial Affairs. “The Peel Plate methods ...
(Date:6/23/2016)... SAN FRANCISCO , June 23, 2016   ... it has secured $1 million in debt financing from ... to ramp up automation and to advance its drug ... for its new facility. "SVB has been ... goes beyond the services a traditional bank would provide," ...
Breaking Biology Technology:
(Date:5/3/2016)... , May 3, 2016  Neurotechnology, a ... the MegaMatcher Automated Biometric Identification System (ABIS) ... large-scale multi-biometric projects. MegaMatcher ABIS can process multiple ... using any combination of fingerprint, face or iris ... MegaMatcher SDK and MegaMatcher Accelerator , ...
(Date:4/28/2016)... April 28, 2016 First quarter 2016:   ... 966% compared with the first quarter of 2015 The ... 589.1 M (loss: 18.8) and the operating margin was 40% (-13) ... Cash flow from operations was SEK 249.9 M (21.2) ... guidance is unchanged, SEK 7,000-8,500 M. The operating margin ...
(Date:4/26/2016)... Research and Markets has announced ... 2016-2020"  report to their offering.  , ,     (Logo: ... analysts forecast the global multimodal biometrics market to ... period 2016-2020.  Multimodal biometrics is being ... the healthcare, BFSI, transportation, automotive, and government for ...
Breaking Biology News(10 mins):